PRAX (Praxis Precision Medicines) Moat Score: 4/10 (As of Jul. 01, 2026)


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $334.79
GF Value $30.73
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Praxis Precision Medicines Moat Score?

Praxis Precision Medicines PRAX -4.50% 38 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $30.73 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, Praxis Precision Medicines ranks better than 88.79% on this metric.

Praxis Precision Medicines has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Praxis Precision Medicines has Narrow Moat: Praxis Precision Medicines Inc has valuable intellectual property and patents in the biotech sector, providing some competitive advantage. However, it faces high R&D costs and regulatory challenges, limiting its moat strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Praxis Precision Medicines might have Narrow Moat - Discernible but modest moat.

Praxis Precision Medicines  (NAS:PRAX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Praxis Precision Medicines Moat Score Related Terms

PRAX vs IBRX, CORT, KYMR: Moat Score Comparison

For the Biotechnology subindustry, Praxis Precision Medicines's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Praxis Precision Medicines Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Moat Score distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Moat Score falls into.


PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Praxis Precision Medicines (PRAX) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Praxis Precision Medicines ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Praxis Precision Medicines' Moat Score too high?
Praxis Precision Medicines' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Praxis Precision Medicines' value of 4 is 100% above this industry median. Based on the distribution chart, Praxis Precision Medicines ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Moat Score compare to IBRX and CORT?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #157 out of 1400 companies for Moat Score. This places Praxis Precision Medicines in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Praxis Precision Medicines' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Praxis Precision Medicines's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Praxis Precision Medicines's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $30.73, compared to a current price of $334.79 — trading 989.5% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Praxis Precision Medicines' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $334.79 is trading 989.5% above its estimated GF Value™ of $30.73. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Moat Score: 4
  • GF Value™: $30.73 vs. price of $334.79 (989.5% above fair value)
  • GF Score™: 38/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1400)

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$334.79
Price
$30.73
GF Value